Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 4
2006 1
2009 1
2014 4
2015 6
2016 4
2017 4
2018 10
2019 8
2020 5
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year
Filters applied: . Clear all
Page 1
Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S. Araki E, et al. Among authors: suganami h. Diabetes Care. 2018 Mar;41(3):538-546. doi: 10.2337/dc17-1589. Epub 2018 Jan 3. Diabetes Care. 2018. PMID: 29298800 Clinical Trial.
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S; K-877 Study Group. Arai H, et al. Among authors: suganami h. J Atheroscler Thromb. 2018 Jun 1;25(6):521-538. doi: 10.5551/jat.44412. Epub 2018 Apr 7. J Atheroscler Thromb. 2018. PMID: 29628483 Free PMC article. Clinical Trial.
Restricted mean survival time as a summary measure of time-to-event outcome.
Hasegawa T, Misawa S, Nakagawa S, Tanaka S, Tanase T, Ugai H, Wakana A, Yodo Y, Tsuchiya S, Suganami H; JPMA Task Force Members. Hasegawa T, et al. Among authors: suganami h. Pharm Stat. 2020 Jul;19(4):436-453. doi: 10.1002/pst.2004. Epub 2020 Feb 18. Pharm Stat. 2020. PMID: 32072769
Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin.
Matsubayashi Y, Yoshida A, Suganami H, Osawa T, Furukawa K, Suzuki H, Fujihara K, Tanaka S, Kaku K, Sone H. Matsubayashi Y, et al. Among authors: suganami h. Diabetes Obes Metab. 2020 Jun;22(6):947-956. doi: 10.1111/dom.13980. Epub 2020 Feb 14. Diabetes Obes Metab. 2020. PMID: 31984623 Free PMC article. Clinical Trial.
Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.
Sato Y, Nunoi K, Kaku K, Yoshida A, Suganami H. Sato Y, et al. Among authors: suganami h. Diabetes Obes Metab. 2020 Feb;22(2):222-230. doi: 10.1111/dom.13890. Epub 2019 Nov 14. Diabetes Obes Metab. 2020. PMID: 31608549 Free PMC article. Clinical Trial.
Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan.
Sakamaki K, Yoshida S, Morita Y, Kamiura T, Iba K, Ogawa N, Suganami H, Tsuchiya S, Fukimbara S. Sakamaki K, et al. Among authors: suganami h. Ther Innov Regul Sci. 2019 Jun 18:2168479019855994. doi: 10.1177/2168479019855994. Online ahead of print. Ther Innov Regul Sci. 2019. PMID: 31213076
47 results